Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$104.92 -0.5%	$100.58	$76.53 ▼ $131.49	$25.22B	1.29	942,558 shs	1.52 million shs
BPMC Blueprint Medicines	$128.21 +0.2%	$99.05	$73.04 ▼ $128.50	$8.28B	0.84	1.18 million shs	4.65 million shs
ONC Beigene	$276.53 +5.4%	$240.18	$141.31 ▼ $287.88	$32.74B	0.3	451,591 shs	724,269 shs
SMMT Summit Therapeutics	$20.16 +3.0%	$23.61	$6.78 ▼ $36.91	$14.97B	-1.06	3.62 million shs	3.64 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	-0.51%	-4.75%	+11.03%	+5.48%	+7.16%
BPMC Blueprint Medicines	+0.20%	+0.24%	+28.98%	+43.12%	+20.79%
ONC Beigene	+5.38%	+7.60%	+23.05%	+6.69%	+27,652,999,900.00%
SMMT Summit Therapeutics	+2.96%	+2.18%	-18.08%	-3.03%	+144.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTX BioNTech	2.878 of 5 stars	4.4	3.0	2.5	0.8	0.0
BPMC Blueprint Medicines	1.1757 of 5 stars	2.2	2.0	2.6	0.8	0.6
ONC Beigene	1.3529 of 5 stars	2.5	0.0	2.2	1.7	0.6
SMMT Summit Therapeutics	2.9198 of 5 stars	4.4	3.0	2.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.83	Moderate Buy	$138.25	31.76% Upside
BPMC Blueprint Medicines	2.32	Hold	$129.35	0.89% Upside
ONC Beigene	3.00	Buy	$319.00	15.36% Upside
SMMT Summit Therapeutics	2.77	Moderate Buy	$35.09	74.06% Upside

Current Analyst Ratings Breakdown

Latest BPMC, ONC, BNTX, and SMMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	SMMT Summit Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
6/11/2025	SMMT Summit Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$12.00
6/5/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$134.00 ➝ $145.00
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$132.00
6/3/2025	BNTX BioNTech	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$151.00 ➝ $155.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$2.75B	9.18	$4.51 per share	23.25	$92.17 per share	1.14
BPMC Blueprint Medicines	$562.12M	14.73	N/A	N/A	$4.67 per share	27.45
ONC Beigene	$4.18B	7.84	N/A	N/A	$37.10 per share	7.45
SMMT Summit Therapeutics	$700K	21,388.78	N/A	N/A	$0.11 per share	183.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	$1.01B	-$3.40	N/A	N/A	N/A	-15.16%	-2.35%	-2.05%	8/4/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	197.25	N/A	-13.19%	-77.49%	-20.84%	7/30/2025 (Estimated)
ONC Beigene	-$881.71M	-$3.72	N/A	389.48	7.73	-25.94%	-25.12%	-14.95%	N/A
SMMT Summit Therapeutics	-$614.93M	-$0.34	N/A	N/A	N/A	N/A	-85.42%	-52.66%	8/5/2025 (Estimated)

Latest BPMC, ONC, BNTX, and SMMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	ONC Beigene	-$0.71	$1.22	+$1.93	$0.01	$1.12 billion	$1.12 billion
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	$1.53	1.46%	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
ONC Beigene	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	7.33	7.21
BPMC Blueprint Medicines	1.15	2.85	2.80
ONC Beigene	0.05	1.93	1.72
SMMT Summit Therapeutics	N/A	8.31	8.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
BPMC Blueprint Medicines	N/A
ONC Beigene	48.55%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
BPMC Blueprint Medicines	4.21%
ONC Beigene	6.62%
SMMT Summit Therapeutics	84.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	3,080	240.39 million	193.71 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.22 million	Optionable
ONC Beigene	9,000	118.38 million	90.59 million	N/A
SMMT Summit Therapeutics	110	742.67 million	86.28 million	Optionable

BPMC, ONC, BNTX, and SMMT Headlines

Recent News About These Companies

Polianta Ltd Takes $1.17 Million Position in Summit Therapeutics Inc. (NASDAQ:SMMT)

June 13 at 6:02 AM | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Trading Up 5.1% - Time to Buy?

June 12 at 4:58 PM | marketbeat.com

These 24 Stocks Are Ripe for a Short Squeeze

June 12 at 3:11 PM | schaeffersresearch.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 12 at 9:00 AM | prnewswire.com

Summit Therapeutics (NASDAQ:SMMT) Rating Increased to Strong Sell at Leerink Partnrs

June 12 at 7:52 AM | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Now Covered by Leerink Partners

June 12 at 3:57 AM | americanbankingnews.com

Research Analysts Issue Forecasts for SMMT FY2026 Earnings

June 12 at 2:23 AM | americanbankingnews.com

Leerink Partners Initiates Coverage of Summit Therapeutics (SMMT) with Underperform Recommendation

June 11 at 11:38 PM | msn.com

Merck rival Summit draws a rare sell-equivalent rating

June 11 at 6:37 PM | msn.com

Why Summit Therapeutics Stock Tanked Today

June 11 at 6:01 PM | fool.com

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Here's Why

June 11 at 12:30 PM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 11 at 9:00 AM | accessnewswire.com

Summit Therapeutics (NASDAQ:SMMT) Earns Underperform Rating from Analysts at Leerink Partners

June 11 at 8:24 AM | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up - Here's What Happened

June 10 at 11:35 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 10 at 9:00 AM | globenewswire.com

Equities Analysts Set Expectations for SMMT FY2026 Earnings

June 10 at 8:30 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 9, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 7, 2025 | prnewswire.com

Summit Therapeutics Inc. (NASDAQ:SMMT) Receives $37.40 Average PT from Analysts

June 7, 2025 | americanbankingnews.com

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 6, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Beaten-Down Stocks Trading 50% Below Their 52-Week Highs
By Leo Miller | May 27, 2025
View 3 Beaten-Down Stocks Trading 50% Below Their 52-Week Highs
Turbulence for Joby Shares: What's Behind the Recent Dip?
By Jeffrey Neal Johnson | May 22, 2025
View Turbulence for Joby Shares: What's Behind the Recent Dip?
Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern
By Leo Miller | June 2, 2025
View Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern
RKLB Breakout Fails Near Highs: Should Investors Be Concerned?
By Ryan Hasson | June 11, 2025
View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?
Palantir Soars on Government Deals as Valuation Debate Lingers
By Chris Markoch | June 3, 2025
View Palantir Soars on Government Deals as Valuation Debate Lingers

BPMC, ONC, BNTX, and SMMT Company Descriptions

BioNTech NASDAQ:BNTX

$104.92 -0.54 (-0.51%)

Closing price 06/12/2025 04:00 PM Eastern

Extended Trading

$106.18 +1.26 (+1.20%)

As of 08:30 AM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Blueprint Medicines NASDAQ:BPMC

$128.21 +0.26 (+0.20%)

Closing price 06/12/2025 04:00 PM Eastern

Extended Trading

$127.97 -0.24 (-0.19%)

As of 08:24 AM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Beigene NASDAQ:ONC

$276.53 +14.12 (+5.38%)

As of 06/12/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Summit Therapeutics NASDAQ:SMMT

$20.16 +0.58 (+2.96%)

Closing price 06/12/2025 04:00 PM Eastern

Extended Trading

$19.76 -0.40 (-1.98%)

As of 08:32 AM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time